Orchestra BioMed Holdings (OBIO) Free Cash Flow (2021 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Free Cash Flow of -$22.4 million for Q1 2026, down 33.62% year-over-year from -$33.7 million in Q1 2025, and down 848.32% quarter-over-quarter from -$2.4 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) Free Cash Flow (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Free Cash Flow for 6 consecutive years, with -$22.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 33.62% year-over-year to -$22.4 million; the TTM figure through Mar 2026 stood at -$54.8 million (down 0.56% YoY), while the FY2025 annual figure was -$49.1 million, up 3.37% from the prior year.
- Free Cash Flow slipped to -$22.4 million in Q1 2026 per OBIO's latest filing, from -$2.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$2.4 million in Q4 2025 and bottomed at -$22.4 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$11.7 million across 5 years, with a median of -$11.0 million in 2023.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 30411.53% — and 2025, when it jumped 82.73%.
- Orchestra BioMed Holdings' Free Cash Flow stood at -$8.8 million in 2022, then decreased by 24.7% to -$11.0 million in 2023, then declined by 24.36% to -$13.6 million in 2024, then surged by 82.73% to -$2.4 million in 2025, then tumbled by 848.32% to -$22.4 million in 2026.
- Business Quant data shows OBIO's Free Cash Flow at -$22.4 million in Q1 2026, -$2.4 million in Q4 2025, and -$14.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | -19.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.59 Mn |
| Jun 30, 2026 | -19.59 Mn |
| Mar 31, 2026 | -22.35 Mn |
| Mar 31, 2026 | -22.35 Mn |
| Dec 31, 2025 | -2.36 Mn |
| Dec 31, 2025 | -2.36 Mn |
| Sep 30, 2025 | -14.49 Mn |
| Sep 30, 2025 | -14.49 Mn |
| Jun 30, 2025 | -15.56 Mn |
| Jun 30, 2025 | -15.56 Mn |
| Mar 31, 2025 | -16.73 Mn |
| Mar 31, 2025 | -16.73 Mn |
| Dec 31, 2024 | -13.64 Mn |
| Dec 31, 2024 | -13.64 Mn |
| Sep 30, 2024 | -13.77 Mn |
| Sep 30, 2024 | -13.77 Mn |
| Jun 30, 2024 | -10.31 Mn |
| Jun 30, 2024 | -10.31 Mn |
| Mar 31, 2024 | -13.12 Mn |
| Mar 31, 2024 | -13.12 Mn |